Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Northwell Health is now offering a new injection that promises to reduce the risk of HIV and AIDS. Doctors say it will combat ...

Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...